These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2006-001001-28||Double-blind, placebo controlled, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of GTx-024 in Postmenopausal Females and Elderly Males||2006-11-15||due-trials|
|Not reported||2011-001791-19||Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy||2014-06-25||due-trials|
|Not reported||2011-001792-39||Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemothera...||2014-06-25||due-trials|
|Not reported||2012-004825-26||Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with castration resistant prostate cancer maintained on androg...||2016-11-09||due-trials|
|Not reported||2014-004989-23||A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)||2018-05-18||due-trials|
|Listed as ongoing, but also has a completion date||2015-001012-35||A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Po...||2018-12-03||bad-data|